Black Diamond Therapeutics (NASDAQ:BDTX) Upgraded at Wall Street Zen

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a note issued to investors on Saturday.

BDTX has been the subject of several other research reports. HC Wainwright lifted their price objective on Black Diamond Therapeutics from $11.00 to $12.00 and gave the stock a "buy" rating in a report on Tuesday, March 18th. Wedbush reissued an "outperform" rating and set a $11.00 price objective on shares of Black Diamond Therapeutics in a report on Wednesday, March 19th. Finally, Stifel Nicolaus dropped their price objective on Black Diamond Therapeutics from $16.00 to $15.00 and set a "buy" rating on the stock in a report on Friday, March 7th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $14.60.

Black Diamond Therapeutics Stock Performance

Shares of BDTX opened at $2.31 on Friday. The business has a 50-day moving average of $1.86 and a 200 day moving average of $2.04. Black Diamond Therapeutics has a fifty-two week low of $1.20 and a fifty-two week high of $6.75. The firm has a market cap of $131.35 million, a P/E ratio of -1.74 and a beta of 2.71.

Insider Buying and Selling at Black Diamond Therapeutics

In other Black Diamond Therapeutics news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of the firm's stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $2.07, for a total value of $11,973,484.44. Following the sale, the insider now owns 2,733,547 shares of the company's stock, valued at $5,658,442.29. This trade represents a 67.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 5.97% of the company's stock.

Institutional Trading of Black Diamond Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. D. E. Shaw & Co. Inc. bought a new position in shares of Black Diamond Therapeutics during the 4th quarter valued at about $37,000. Intech Investment Management LLC increased its position in shares of Black Diamond Therapeutics by 49.1% during the 4th quarter. Intech Investment Management LLC now owns 19,247 shares of the company's stock valued at $41,000 after purchasing an additional 6,340 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Black Diamond Therapeutics by 429.6% during the 4th quarter. JPMorgan Chase & Co. now owns 18,929 shares of the company's stock valued at $41,000 after purchasing an additional 15,355 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Black Diamond Therapeutics during the 4th quarter valued at about $42,000. Finally, Wells Fargo & Company MN increased its position in shares of Black Diamond Therapeutics by 41.8% during the 4th quarter. Wells Fargo & Company MN now owns 20,119 shares of the company's stock valued at $43,000 after purchasing an additional 5,932 shares during the last quarter. Hedge funds and other institutional investors own 95.47% of the company's stock.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.